Circulation

SEPTEMBER 24, 2024

In addition, the advent of new care models, including virtual and remote delivery of cardiac rehabilitation services, has expanded the ways that cardiac rehabilitation programs can reach patients.

Cardiac Rehabilitation 78

Cardiac Rehabilitation Pulmonary Health Disparities Cardiovascular Disease 78

Frontiers in Cardiovascular Medicine

MARCH 30, 2025

The independent risk factors for mortality included left ventricular ejection fraction (LVEF), pulmonary hypertension, and low-density lipoprotein (LDL) levels (P<0.05). LVEF, pulmonary hypertension, and LDL levels are critical prognostic factors, offering insights for risk assessment and management in affected children.

Risk Factors 52

Risk Factors Pediatrics Cardiomyopathy Pulmonary 52

HCPLive

JUNE 4, 2024

This review of May 2024 covered several notable topics in the pulmonary health field, including research into vaping, lung abnormalities, and treatment of COPD.

Pulmonary 59

Pulmonary Research 59

HCPLive

MAY 1, 2024

In this review of April 2024, the editorial team highlighted some of the biggest stories in the pulmonary health space, touching on topics such as air quality issues, asthma, and pneumonia.

Pulmonary 59

Pulmonary 59

Society of Thoracic Surgeons - Research

APRIL 2, 2024

News STS Panel Discussion: Predictors of Venous Thromboembolism after Pulmonary Resection for Lung Cancer KCummings Tue, 04/02/2024 - 08:33 1 min read

Cancer 64

Cancer Pulmonary 64

Circulation

NOVEMBER 11, 2024

Circulation, Volume 150, Issue Suppl_1 , Page A4120743-A4120743, November 12, 2024. However, the most recurrent cardiac complication in RASopathies is pulmonary valve stenosis (PVS). Backgound:The RASopathies are developmental syndromes resulting from variants in the RAS/mitogen-activated protein (MAPK) cascade.

Stenosis 75

Stenosis Pulmonary Cardiomyopathy Circulation 75

Society of Thoracic Surgeons - Surgeon

OCTOBER 16, 2024

Resource Pulmonary Resection for Lung Cancer Risk Calculator gmckinney Wed, 10/16/2024 - 07:59 The new pulmonary resection for lung cancer risk calculator is engineered using contemporary data from the STS General Thoracic Surgery Database.

Cancer 52

Cancer Pulmonary Hospital Outcomes 52

Frontiers in Cardiovascular Medicine

APRIL 3, 2025

Complex cases included patients with large defects (25mm), multiple or fenestrated ASDs, deficient posterior-inferior rim <3mm, deficient retro-aortic rim <5mm, pulmonary hypertension, septal malalignment, and pregnancy. Patients were categorized into two groups based on the complexity of their cases (simple vs. complex ASD cases).

Ultrasound 52

Ultrasound Pulmonary Hypertension Aortic 52

Frontiers in Cardiovascular Medicine

DECEMBER 23, 2024

BackgroundPercutaneous mechanical thrombectomy (PMT) is increasingly used in the treatment of intermediate and high-risk acute pulmonary embolism (PE), and the treatment of high-risk PE with the aid of veno-arterial extracorporeal membrane oxygenation (VA-ECMO) has also been reported. The mortality rate was 27.3% during the 90-day follow-up.

Embolism 52

Embolism Pulmonary Cardiac Arrest Biomarkers 52

DAIC

SEPTEMBER 4, 2024

tim.hodson Wed, 09/04/2024 - 15:34 Aug. 29, 2024 – Jupiter Endovascular, Inc., SPIRARE II is a prospective, single-arm, multicenter pivotal trial that will enroll up to 145 patients with acute, intermediate-risk PE treated with the Vertex Pulmonary Embolectomy System at up to 25 U.S. recently announced that the U.S.

Pulmonary 52

Pulmonary Embolism Technology Anatomy 52

HCPLive

SEPTEMBER 4, 2024

This Month in Review summarizes some of the most significant stories covered in the month of August in the pulmonary health space, including new research and FDA news.

Pulmonary 52

Pulmonary Research 52

Dr. S. Venkatesan MD

OCTOBER 15, 2024

A new Intelligent thrombo-suction catheter system , is being introduced for treatment of acute pulmonary embolism.This device regulates the force with which thrombus is sucked , with less injury and bleeding and better outcomes. Human studies & Evidence The experience from this device was presented in ESC 2024 London.

Technology 52

Technology Pulmonary Embolism Innovation 52

Ken Grauer, MD

SEPTEMBER 15, 2024

== Review of ECG Rhythms — MIS-C Case Report ( 9/5 /2024 ): == What follows below are my first impressions of the ECG rhythms sent to me from the Case Report by Dimah Jarmakani et al — of a 12-year old boy with MIS-C ( M ultisystem I nflammatory S yndrome in C hildren ). RED arrows show what looks to be sinus P waves that are HUGE !!!!

Arrhythmia 78

Arrhythmia Bradycardia Heart Failure Pacemaker 78

DAIC

FEBRUARY 6, 2024

Getty Images milla1cf Tue, 02/06/2024 - 20:36 February 6, 2024 — Cortex announced the initiation of its RESOLVE-AF trial ( NCT05883631 ), a study formally launched in late October 2023. The Ablamap System includes a workstation with software and monitor, amplifier, and proprietary basket mapping catheter and cables. "I

Ablation 104

Ablation Atrial Fibrillation AFIB Pulmonary 104

The British Journal of Cardiology

JANUARY 16, 2024

Pulmonary hypertension is a rare disease, associated with a significant deterioration in quality of life, usually not curable and with an ominous prognosis. We present the case of a patient diagnosed with precapillary component pulmonary hypertension, with the finding of an arteriovenous fistula at the peripheral level.

Pulmonary 52

Pulmonary Hypertension Quality of Life Article 52

Society of Thoracic Surgeons - Allied Health

NOVEMBER 16, 2023

Event 2024 STS Coding Workshop dkaczmarek Thu, 11/16/2023 - 11:37 Event dates Feb 23–24, 2024 Register Now Location Virtual Register Now Add to calendar. Upon completion of this activity, participants should be able to:  Identify new CPT codes, updates, and payment policies affecting cardiothoracic surgery coding for 2024.

Cardiothoracic 52

Cardiothoracic Reimbursement Best Practices Education 52

DAIC

MAY 22, 2024

milla1cf Wed, 05/22/2024 - 07:00 May 22, 2024 — Voiant (USA) and Thirona (The Netherlands) announced they have entered a global commercial partnership, combining Voiant's expertise in supporting clinical trials in pulmonary drug and treatment development with Thirona's expertise in advanced lung image analysis.

Pulmonary 52

Pulmonary Research Outcomes 52

DAIC

MARCH 26, 2024

milla1cf Tue, 03/26/2024 - 11:12 March 26, 2024 — Medical imaging AI company Avicenna.AI announced that it has received 510(k) clearance from the US Food and Drug Administration for its CINA-iPE and CINA-ASPECTS products. CINA-iPE and CINA-ASPECTS are the latest tools from Avicenna.AI

Embolism 105

Embolism Pulmonary Blood Clot Cancer 105

DAIC

FEBRUARY 4, 2025

4, 2025 Riverain Technologies recently announced it expanded across eight countries in 2024 and added nearly 50 new customers with its ClearRead solutions to clearly, confidently and quickly detect cardiothoracic diseases. Our 2024 growth was driven by strong product market acceptance through network effects. MD, Thrap, K.,

Technology 52

Technology Cardiothoracic Cancer Pulmonary 52

DAIC

JULY 31, 2024

mtaschetta-millane Wed, 07/31/2024 - 07:00 July 31, 2024 — BioCardia, Inc. , a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, reported it has submitted a 510(k) for approval of its patented Morph DNA Steerable Introducer Sheath.

Myocardial Infarction 99

Myocardial Infarction Technology Angina Pulmonary 99

American College of Cardiology

JUNE 28, 2024

Here are my takeaways for what's likely to affect practice in the short and medium-term.

Peripheral Arterial Disease 40

Peripheral Arterial Disease Embolism Technology Pulmonary 40

Dr. Smith's ECG Blog

SEPTEMBER 23, 2024

In patients with narrow QRS ( not this patient), this pattern is highly suggestive of acute pulmonary embolism. Although it was technically difficult and the quality therefore leaves a lot to be desired, you can still make out RV dilation and septal flattening which is much more suggestive of pulmonary embolism than OMI.

Cardiogenic Shock 127

Cardiogenic Shock Ultrasound Tachycardia Pulmonary 127

DAIC

JUNE 4, 2024

Late-breaking Clinical Trial Results from FARADISE, admIRE Study and Advent Trial at Heart Rhythm 2024 Highlight Pulsed Field Ablation Developments for Atrial Fibrillation Treatment 8. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF) 10.

Preserved Ejection Fraction 105

Preserved Ejection Fraction Peripheral Arterial Disease Heart Failure Atrial Fibrillation 105

HCPLive

MARCH 26, 2024

The US FDA approval of sotatercept for PAH was announced by Merck on March 26, 2024.

Pulmonary 59

Pulmonary Hypertension 59

DAIC

JANUARY 31, 2024

A company statement reported that its PFA System is indicated for the isolation of pulmonary veins in the treatment of drug-refractory, recurrent, symptomatic, paroxysmal (i.e., Image courtesy: Boston Scientific christine.book Wed, 01/31/2024 - 11:13 January 31, 2024 — Boston Scientific Corporation announced it has received U.S.

Ablation 111

Ablation Atrial Fibrillation Anatomy Pulmonary 111

Circulation

NOVEMBER 11, 2024

Circulation, Volume 150, Issue Suppl_1 , Page A4143390-A4143390, November 12, 2024. Introduction:Obesity is rising in prevalence worldwide and co-exists in patients with group 1 pulmonary hypertension (PH). Despite having group 1 PH, pulmonary capillary wedge pressure (PCWP) was higher with obesity (13.8 ± 6.3 vs 10.4 ± 6.5

Obesity 40

Obesity Pulmonary Hypertension Diabetes 40

Circulation

NOVEMBER 11, 2024

Circulation, Volume 150, Issue Suppl_1 , Page A4142839-A4142839, November 12, 2024. Introduction:Inflammation is a key driver in the development of pulmonary arterial hypertension (PAH). The pulmonary vasculature was evaluated histologically. The gut microbiome is a complex ecosystem consisting of trillions of organisms, 0.1%

Pulmonary 40

Pulmonary Hypertension Innovation Exercise 40

Nature Reviews - Cardiology

FEBRUARY 21, 2024

Nature Reviews Cardiology, Published online: 22 February 2024; doi:10.1038/s41569-024-01002-4 Using a porcine model of cardiogenic shock, Lamberti and colleagues develop a clinically accessible, patient-validated metric to assess pulmonary vascular compliance that can predict tolerance to left-sided ventricular assist device support.

Cardiogenic Shock 40

Cardiogenic Shock Pulmonary 40

American College of Cardiology

SEPTEMBER 2, 2024

Compared with a sham procedure, pulmonary vein isolation resulted in a statistically significant and clinically important decrease in atrial fibrillation (AFib) burden at six months, according to results from the SHAM-PVI trial presented at ESC Congress 2024 in London and simultaneously published in JAMA.

AFIB 40

AFIB Pulmonary Quality of Life Atrial Fibrillation 40

Medical Xpress - Cardiology

MAY 3, 2024

Late-breaking data from the ENGULF trial showed that a novel dual-action thrombectomy device was effective and safe in treating acute pulmonary embolism (PE).

Embolism 40

Embolism Pulmonary 40

DAIC

JUNE 13, 2024

Xeltis synthetic restorative pulmonary heart valve evolves into a fully functioning, natural heart valve through colonization by the patient’s own tissue.

Heart Valves 111

Heart Valves Technology Pulmonary Outcomes 111

Journal of Cardiothoracic Surgery

MARCH 5, 2025

Introduction The aim of this study was to evaluate the efficacy of the 4-hook needle localization for pulmonary ground glass nodules (GGNs).

Pulmonary 52

Pulmonary Hemorrhage Research 52

HCPLive

MAY 20, 2024

These late-breaking data on drug candidate ENV-101 were presented at ATS 2024 and resulted from a new study on the drug’s effect on individuals with IPF.

Pulmonary 59

Pulmonary 59

Journal of Cardiovascular Pharmacology

JULY 1, 2024

However, whether AMOTL2 is linked to pulmonary arterial hypertension (PAH) has not been addressed. Overexpression of AMOTL2 also led to a noteworthy decrease in vascular wall thickness, pulmonary artery area, and collagen deposition in rats with PAH. Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.

Pulmonary 40

Pulmonary Hypertension Physiology Article 40

DAIC

APRIL 18, 2024

Graphic courtesy of Dan Musat milla1cf Thu, 04/18/2024 - 13:32 April 18, 2024 — New evidence-based research calls into question the conventional three-month blanking period immediately after atrial fibrillation (AF) ablation, when early occurrences of AF are thought not to predict long-term AF recurrence.

Atrial Fibrillation 111

Atrial Fibrillation Ablation Heart Rhythm Article 111

Circulation

NOVEMBER 11, 2024

Circulation, Volume 150, Issue Suppl_1 , Page A4145487-A4145487, November 12, 2024. reported several cases in which right lower pulmonary vein (RLPV) thrombi extended into the left atrium (LA). Thrombi are difficult to visualize directly and are recognized as lacking in pulmonary vein blood flow. This study had two limitations.

Pulmonary 40

Pulmonary Diabetes Atherosclerosis Heart Disease 40

HCPLive

JANUARY 25, 2024

On January 25, 2024, the day following the proposed PDUFA goal date, Liquidia Corporation announced the FDA was still reviewing the NDA for pulmonary hypertension with interstitial lung disease for treprostinil inhalation powder (Yutrepia).

Pulmonary 69

Pulmonary Hypertension 69